Pre‐eclampsia · women with obesity during pregnancy
Metformin showed no clear difference in pre‐eclampsia compared with placebo (low certainty).
1 finding from 1 review
Gestational diabetes · women with obesity during pregnancy
Metformin showed no clear difference in gestational diabetes (as defined by the trial authors) compared with placebo (moderate certainty).
1 finding from 1 review
Diarrhoea · women with obesity during pregnancy
Metformin leads to higher adverse effects associated with the treatment: diarrhoea compared with placebo (high certainty).
1 finding from 1 review
Birthweight (g) · women with obesity during pregnancy
1 finding from 1 review
Live birth rate per woman · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Metformin showed no clear difference in live birth rate per woman compared with placebo or no treatment (low certainty).
1 finding from 1 review
Menstrual frequency per woman · women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Gastrointestinal adverse events · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Metformin probably leads to higher adverse events (gastrointestinal) per woman compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Miscarriage · women with polycystic ovary syndrome
It is very uncertain whether metformin changes miscarriage rate per woman compared with clomiphene citrate (very low certainty).
1 finding from 1 review
Clinical pregnancy rate · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Metformin probably leads to higher clinical pregnancy rate per woman compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Menstrual frequency per woman · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Metformin may leads to higher menstrual frequency per woman compared with placebo or no treatment (low certainty).
1 finding from 1 review
Ovulation rate · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Metformin probably leads to higher ovulation rate per woman compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Miscarriage · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Metformin showed no clear difference in miscarriage rate per woman compared with placebo or no treatment (low certainty).
1 finding from 1 review
Live birth rate per woman · subfertile women with polycystic ovary syndrome
Metformin may leads to higher live birth rate (per woman) compared with placebo co‐treatment (low certainty).
1 finding from 1 review
Multiple pregnancy rate · subfertile women with polycystic ovary syndrome
Metformin showed no clear difference in multiple pregnancy rate (per woman) compared with placebo co‐treatment (low certainty).
1 finding from 1 review
Ongoing pregnancy · subfertile women with polycystic ovary syndrome
Metformin may leads to higher ongoing pregnancy rate (per woman) compared with placebo co‐treatment (low certainty).
1 finding from 1 review
Clinical pregnancy rate · subfertile women with polycystic ovary syndrome
Metformin may leads to higher clinical pregnancy rate (per woman) compared with placebo co‐treatment (low certainty).
1 finding from 1 review
Weight: clinically important change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Weight: clinically important change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Weight Average endpoint/change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review